FDA Approves AstraZeneca’s SEROQUEL(R) For Bipolar Depression Treatment 
AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL(R) (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder** and for the treatment of schizophrenia. [click link for full